Best Peptides for Weight Loss in 2026

The ultimate guide to metabolic peptides, their mechanisms, and how they stack for optimal body composition.

---

Educational content only. Not medical advice. The compounds discussed include FDA-approved medications, investigational drugs, and substances available through compounding pharmacies under physician supervision. Consult a licensed healthcare provider before beginning any weight-loss protocol.

---

The peptide weight-loss conversation in 2026 looks dramatically different than it did even three years ago. The first generation of GLP-1 medications — Ozempic and Wegovy (semaglutide) — established that pharmaceutical weight loss in the 12-15% body weight range was achievable for most patients. The second generation, led by tirzepatide (Mounjaro/Zepbound), pushed the ceiling to 20%. And the third generation, with retatrutide showing 28-30% weight loss in its Phase 3 readouts, is now on the horizon for FDA submission.

That's the headline shift. Underneath it, the landscape includes other compounds — some FDA-approved, some investigational, some used off-label through compounding pharmacies — that play different roles for different patient profiles. This guide covers what's actually being used in 2026, what the evidence supports, and how to think about the choices.

The Three That Matter Most Right Now

If you're looking at peptide-based weight loss in early-to-mid 2026, three compounds dominate the conversation. All three are GLP-1 receptor agonists or related incretin-system drugs. All three have substantial clinical evidence. All three have meaningfully different efficacy ceilings.

Semaglutide (Ozempic, Wegovy, Rybelsus)

Mechanism: Single GLP-1 receptor agonist. Slows gastric emptying, reduces appetite signals to the brain, improves insulin sensitivity.

Expected weight loss: Approximately 13-15% mean body weight reduction over 68-72 weeks at the full 2.4 mg dose, based on STEP-1 trial data.

FDA status: Approved for chronic weight management (Wegovy) since 2021. Approved for type 2 diabetes (Ozempic) since 2017. Oral formulation (Rybelsus) approved for diabetes since 2019.

Cost: Approximately $1,350/month retail without insurance for Wegovy.

Best fit: Patients new to GLP-1 therapy where insurance coverage favors semaglutide, patients who prefer or require an oral option (Rybelsus for diabetes), patients who have tolerated semaglutide well and are meeting goals.

Tirzepatide (Mounjaro, Zepbound)

Mechanism: Dual GIP/GLP-1 receptor agonist. The dual-receptor approach appears to produce additive effects on appetite suppression and metabolic regulation compared with single GLP-1 activation.

Expected weight loss: Approximately 20% mean body weight reduction over 72 weeks based on SURMOUNT-5 head-to-head trial data (NEJM, 2025) — significantly superior to semaglutide in direct comparison.

FDA status: Approved for type 2 diabetes (Mounjaro) since 2022. Approved for chronic weight management (Zepbound) since 2023.

Cost: Approximately $1,060/month retail without insurance for Zepbound.

Best fit: Patients prioritizing maximum weight loss where access is available, patients who have plateaued on semaglutide, patients with type 2 diabetes alongside obesity.

For a detailed head-to-head, see our Tirzepatide vs Semaglutide comparison.

Retatrutide (investigational)

Mechanism: Triple agonist — GIP, GLP-1, and glucagon receptor activation. The glucagon receptor activity is the novel addition, potentially contributing additional effects on energy expenditure beyond the appetite suppression mechanism of GLP-1 alone.

Expected weight loss: TRIUMPH-1 Phase 3 data (announced May 21, 2026) showed 28.3% mean body weight reduction at 80 weeks on the 12 mg dose, with continued weight loss in the extension trial reaching 30.3% at 104 weeks. Roughly 45% of participants achieved at least 30% weight loss. The TRIUMPH-4 trial in obesity with knee osteoarthritis showed 28.7% weight loss at 68 weeks.

FDA status: Not yet approved. Eli Lilly indicated regulatory submission anticipated in 2026, with FDA approval potentially in 2027. Available through clinical trial enrollment and, in some cases, through specialty compounding pharmacies under physician supervision.

Cost: Pricing not established for commercial sale; clinical trial participants receive the drug at no cost.

Best fit: Patients with significant weight to lose where the additional efficacy ceiling matters, patients enrolled in TRIUMPH-program clinical trials, patients working with physicians who have established access to compounded forms.

The Second Tier — Smaller Roles, Specific Profiles

Beyond the three headline compounds, several other peptides play specific roles in weight-loss protocols, often in combination with primary GLP-1 therapy or for specific patient profiles.

AOD-9604

Mechanism: Synthetic fragment of human growth hormone, specifically the C-terminus portion (amino acids 177-191). Promotes lipolysis (fat breakdown) without the broader anabolic effects of full-length growth hormone.

Evidence: Several small clinical trials in the early 2000s showed modest fat loss benefits in obese patients, though results have been mixed and trial sizes have been small.

Status: Not FDA-approved. Returned to FDA Category 1 status following the February 2026 reclassification, making it accessible through licensed compounding pharmacies with a physician's prescription.

Best fit: As an adjunct to other weight-loss approaches, particularly in patients focused on body composition (fat loss vs lean mass preservation) rather than absolute weight loss.

Tesamorelin (Egrifta)

Mechanism: Growth hormone releasing hormone (GHRH) analog. Stimulates pulsatile growth hormone release, which influences body composition.

Evidence: FDA-approved for HIV-associated lipodystrophy. Specifically reduces visceral adipose tissue (the deep abdominal fat associated with metabolic risk) more than peripheral fat.

Status: FDA-approved for HIV-associated lipodystrophy. Used off-label for visceral adiposity reduction in other patient populations.

Best fit: Patients with disproportionate visceral fat accumulation, particularly when accompanied by markers of metabolic syndrome.

Cagrilintide

Mechanism: Long-acting amylin analog. Amylin is co-secreted with insulin and contributes to satiety and slowed gastric emptying. Cagrilintide is being studied both as monotherapy and in combination with semaglutide.

Evidence: Phase 2 and ongoing Phase 3 trials show meaningful additional weight loss when combined with semaglutide. The CagriSema combination (cagrilintide + semaglutide) has shown weight loss results approaching tirzepatide levels.

Status: Not yet FDA-approved as a single agent. Combination products under regulatory development.

Best fit: Patients participating in CagriSema clinical trials or seeking access through specialty channels.

The Compounded GLP-1 Question

One regulatory point worth addressing directly: a substantial market exists in 2026 for compounded versions of semaglutide and tirzepatide, often offered through telehealth platforms at price points well below the manufacturer-supplied versions.

The regulatory situation is nuanced. Compounded versions of FDA-approved drugs are generally permitted under 503A when the FDA has declared the drug to be in shortage (during which time compounding pharmacies can prepare alternatives) and prohibited when the shortage is declared resolved. Semaglutide and tirzepatide have moved in and out of shortage status, which has correspondingly opened and closed compounding pathways at various times.

The practical implications for patients:

• Compounded versions vary substantially in quality. Some compounding pharmacies operate to the highest 503A standards; others do not. Verifying pharmacy credentials is essential.
• Compounded semaglutide and tirzepatide are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. They use the same active ingredient but may differ in formulation, concentration, and storage requirements.
• Cost differences are real. Compounded versions can cost $200-$500/month versus $1,000+/month for manufacturer-supplied. For patients without insurance coverage, this is a meaningful difference.
• The regulatory situation continues to evolve. What's available through compounding pathways in early 2026 may not be available later in the year as shortage statuses shift.

Anyone considering compounded GLP-1 therapy should do so through a physician who can evaluate pharmacy credentials and ensure quality control.

What Side Effects to Expect

The major side effects across this class of compounds are predictable and largely shared:

Gastrointestinal effects — nausea, vomiting, diarrhea, constipation, abdominal discomfort. Most common during dose escalation (weeks 1-16) and typically diminish substantially once maintenance dose is reached. The single most important factor in tolerance is slow titration. Skipping titration steps reliably produces intolerable nausea.

Reduced appetite — intended, but can become problematic. Patients who lose interest in eating entirely may underconsume protein and nutrients. Working with a dietitian during weight-loss protocols is increasingly common.

Gallbladder effects — increased risk of gallstones, particularly during rapid weight loss. This is a general consequence of weight loss at any rate above approximately 1.5 kg/week.

Thyroid C-cell tumor warning — based on rodent studies. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Pancreatitis risk — patients with prior pancreatitis should be evaluated carefully before starting.

Injection site reactions — generally minor and self-limiting.

For retatrutide specifically, the Phase 3 trials have shown a similar profile to the GLP-1/GIP agonists with no novel safety signals identified to date.

Choosing the Right Weight Loss Peptide for Your Goals

The right peptide for weight loss depends on more factors than just the headline efficacy number. The framework I use with patients:

Factor 1: What can you actually access and afford? The drug that produces the best weight loss for a patient is the one they can actually obtain, afford, and take consistently. If insurance covers semaglutide but not tirzepatide, that's the relevant comparison — not the abstract efficacy difference between them.

Factor 2: What weight loss target makes sense for you? Patients with 30+ lbs to lose may justify the additional efficacy of tirzepatide or, when available, retatrutide. Patients with smaller goals may find semaglutide's profile sufficient.

Factor 3: What's your tolerance picture? All three primary GLP-1s have similar side effect profiles, but individual tolerance varies. Patients who don't tolerate semaglutide may do better on tirzepatide and vice versa — there's no way to predict in advance.

Factor 4: How do you feel about being on a long-term medication? GLP-1 weight loss is largely contingent on continued use. Most patients regain a significant portion of lost weight if they stop the medication. The long-term picture is "ongoing treatment for a chronic condition," not "take the medication until you reach your goal weight and stop."

Factor 5: What does your physician recommend? Beyond the parameters above, an experienced prescribing physician evaluates your full clinical picture in ways that no general guide can replicate.

How PepOS Helps

Whichever peptide you and your physician select, the operational challenge is the same: track every weekly injection, manage the titration schedule, monitor side effects, see whether your weight trend is actually responding to the protocol, and connect your metabolic data to your dosing reality. PepOS is built for exactly this. The Apple Health integration overlays your weight and biometric trends against your protocol timeline. The dose calculator handles reconstitution math if you're using compounded forms. Peppy answers protocol-specific questions with citations to primary literature.

Start your first protocol free

Sources Cited

1. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. 2025. (SURMOUNT-5 trial, NCT05822830)

2. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002. (STEP-1 trial)

3. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216. (SURMOUNT-1 trial)

4. Eli Lilly and Company. TRIUMPH-1 Phase 3 obesity trial topline results — retatrutide. News release, May 21, 2026. (NCT05929066)

5. Eli Lilly and Company. TRIUMPH-4 Phase 3 trial topline results — retatrutide in obesity with knee osteoarthritis. News release, December 11, 2025.

6. Eli Lilly and Company. TRANSCEND-T2D-1 Phase 3 trial topline results — retatrutide in type 2 diabetes. News release, March 19, 2026.

7. U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information. Updated 2024.

8. U.S. Food and Drug Administration. Zepbound (tirzepatide) prescribing information. Updated 2024.

9. U.S. Food and Drug Administration. Egrifta SV (tesamorelin) prescribing information. Updated 2024.

10. AJMC. Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial. American Journal of Managed Care, May 2026.

---

This post is updated as new clinical trial readouts become available. Have a specific protocol question? Open Peppy in the PepOS app.